MedTrace Logo

Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms

NCT00408954 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2010-11-23

No results posted yet for this study

Summary

This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.

Conditions

  • Prostatic Hyperplasia

Interventions

DRUG

UK-369,003

100 mg MR tablet once daily for 2 weeks

DRUG

UK-369,003

UK-369,003-100 mg MR formulation for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Czechia
  • Netherlands
  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00408954 on ClinicalTrials.gov